Haemonetics (HAE -1%) slips on a limp coverage intiation from Goldman Sachs this morning,...

|About: Haemonetics Corp (HAE)|By:, SA News Editor

Haemonetics (HAE -1%) slips on a limp coverage intiation from Goldman Sachs this morning, starting the shares with a Neutral rating and a price target of $47.00. Goldman says the stock is already trading at a premium to both the S&P 500 and its sector peers, and it "limited upside to consensus numbers with management's longterm guidance already contemplating top-line growth ahead of recent trends."